P&T Community, The Online Resource for P&T Decision Makers
Formulary Kits
Login / Register
Join Us     

February 2012

Features

Editorial

When One Size Doesn’t Fit All

CPOE systems should be smarter. Local customization of individual medication-related alerts is a good place to start.
Karl A. Matuszewski, MS, PharmD
FULL TEXT

Commentary

The FDA’s Social Media Guidelines Are Here … Were They Worth the Wait?

The FDA has delivered its highly anticipated guidelines for industry on how to respond to unsolicited requests (via social media platforms) for off-label information about prescription drugs and medical devices. The reviews have been mixed.
Miriam Reisman
FULL TEXT

Cost Analysis Before and After Implementation of a Computerized Physician Order Entry Order Form for Enoxaparin

The authors set out to determine whether a computerized physician order entry (CPOE) order form for enoxaparin would result in a lower cost of drug therapy per day if patients were switched to once-daily administration. Use of the CPOE enoxaparin order form did not reduce the daily cost of therapy, although cost savings did result when the hospital’s protocol was followed.
Rebecca S. Pettit, PharmD, MBA, BCPS; Christopher R. Zimmerman, PharmD, BCPS; Cesar Alaniz, PharmD; and Michael P. Dorsch, PharmD, MS, BCPS
FULL TEXT

Meeting Highlights

34th Annual San Antonio Breast Cancer Symposium and 53rd American Society of Hematology Annual Meeting and Exposition

Walter Alexander
FULL TEXT

Departments

Prescription: Washington

Under Scrutiny: FDA’s REMS for Opioids

Acceptance or Rejection by Stakeholders Will Influence Congress

Some say that the FDA’s proposed REMS opioids initiative does not go far enough to protect patients.
Stephen Barlas
FULL TEXT

Medication Errors

Misprogramming Patient-Controlled Analgesia Levels Causes Dosing Errors

Misprogramming pump levels of patient-controlled analgesia can lead to dosing errors.
Matthew Grissinger, RPh, FASCP
FULL TEXT

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates
FULL TEXT

Pharmaceutical Approval Update

Advate to prevent bleeding; Edarbi and Edarbyclor for hypertension; and Anturol gel for overactive bladder
Marvin M. Goldenberg, PhD, RPh, MS
FULL TEXT

Drug Forecast

Indacaterol (Arcapta Neohaler) for Chronic Obstructive Pulmonary Disease

Arcapta Neohaler for chronic obstructive pulmonary disease
Rachel M. Slaton, PharmD, BCPS; and Danielle L. Cruthirds, PhD
FULL TEXT